Danaher Corp.
Danaher Corporation (DHR) is a diversified science and technology company focused on life sciences, diagnostics and environmental & applied solutions. It supplies instruments, consumables, software and services used by research laboratories, hospitals and industrial customers worldwide. With a market capitalisation of about $155.94 billion, Danaher combines organic R&D-driven growth with disciplined acquisitions and operational rigor (the Danaher Business System) to drive recurring revenue and margin expansion. Investors often watch its exposure to healthcare spending, diagnostic cycles and capital-equipment demand. Strengths include a broad product portfolio, strong cash generation and a track record of integrating acquisitions; risks include execution on M&A, regulatory changes, cyclicality in capital spending and currency swings. Valuation can be premium given its defensive characteristics, but future returns are uncertain. This is general educational information, not personal investment advice — consider your goals and consult an authorised adviser before making investment decisions.
Why It's Moving
Analysts Rally Behind Danaher's Strong Buy Rating with Major Upside Potential into 2026
- Over 20 analysts rate DHR a Buy, with median targets implying over 40% upside from recent levels, signaling confidence in long-term execution.
- Revenue forecasts show average growth to $26.3B in 2026, reflecting expectations of sustained demand in diagnostics and life sciences.
- EPS growth projected at 9.5% on average for 2026, highlighting improving profitability as Danaher leverages its innovation pipeline.
Analysts Rally Behind Danaher's Strong Buy Rating with Major Upside Potential into 2026
- Over 20 analysts rate DHR a Buy, with median targets implying over 40% upside from recent levels, signaling confidence in long-term execution.
- Revenue forecasts show average growth to $26.3B in 2026, reflecting expectations of sustained demand in diagnostics and life sciences.
- EPS growth projected at 9.5% on average for 2026, highlighting improving profitability as Danaher leverages its innovation pipeline.
When is the next earnings date for Danaher Corp. (DHR)?
Danaher's next earnings date is scheduled for April 21, 2026, covering the first quarter of 2026 (Q1 2026). This aligns with the company's historical pattern of late-April releases for Q1 results, following the Q4 2025 report issued on December 31, 2025. Investors should monitor for any updates as the date approaches.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Danaher Corp. stock with a target price of $259.6, indicating potential growth.
Financial Health
Danaher Corp. is performing well, with strong revenue, cash flow, and profit margins.
Dividend
Danaher Corp.'s low dividend yield of 0.68% means it may not be ideal for dividend-seeking investors. If you invested $1000, you would be paid $6.80 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring DHR
Healthcare Titans: Brazil Growth vs Currency Volatility
Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.
Published: October 14, 2025
Explore BasketActivist Sparks Life Science Shakeup
Activist investor Engine Capital is pushing for a sale of life-sciences company Avantor after taking a significant stake. This move could spark a wave of M&A across the life-sciences supply industry, creating opportunities for competitor firms and other potential acquisition targets.
Published: August 11, 2025
Explore BasketAcquirer's Engine
Invest in companies with proven expertise in growth-by-acquisition. These carefully selected stocks represent businesses with exceptional management teams that consistently buy their way to market leadership and enhanced profitability through strategic M&A.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring Revenue Engine
Consumables and service contracts support predictable recurring revenue and cash flow, though demand can vary with spending cycles.
Global Healthcare Reach
A broad international footprint offers diversification across markets, while currency moves and regional regulation remain potential headwinds.
Innovation & M&A
R&D and targeted acquisitions expand capabilities and addressable markets, but integration and valuation risks deserve attention.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
